L-Asparaginase resistance genes in ALL
(Source: Blood)
Source: Blood - May 15, 2019 Category: Hematology Tags: Free Research Articles, CME article CONTINUING MEDICAL EDUCATION (CME) QUESTIONS Source Type: research
Mast cell leukemia and hemophagocytosis in a patient with myelodysplastic syndrome
(Source: Blood)
Source: Blood - May 15, 2019 Category: Hematology Authors: Yang, J., Gabali, A. Tags: Free Research Articles, BloodWork, Myeloid Neoplasia, Phagocytes, Granulocytes, and Myelopoiesis BLOOD WORK Source Type: research
Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation
In conclusion, this MTSS predicts outcome of patients with primary and post-ET/PV myelofibrosis undergoing allogeneic stem cell transplantation. (Source: Blood)
Source: Blood - May 15, 2019 Category: Hematology Authors: Gagelmann, N., Ditschkowski, M., Bogdanov, R., Bredin, S., Robin, M., Cassinat, B., Shahswar, R., Thol, F., Heuser, M., Socie, G., Beelen, D., Triviai, I., Badbaran, A., Kröger, N. Tags: Transplantation, Myeloid Neoplasia Source Type: research
HAP1 loss confers L-asparaginase resistance in ALL by downregulating the calpain-1-Bid-caspase-3/12 pathway
l-Asparaginase (l-ASNase) is a strategic component of treatment protocols for acute lymphoblastic leukemia (ALL). It causes asparagine deficit, resulting in protein synthesis inhibition and subsequent leukemic cell death and ALL remission. However, patients often relapse because of the development of resistance, but the underlying mechanism of ALL cell resistance to l-asparaginase remains unknown. Through unbiased genome-wide RNA interference screening, we identified huntingtin associated protein 1 (HAP1) as an ALL biomarker for l-asparaginase resistance. Knocking down HAP1 induces l-asparaginase resistance. HAP1 interacts...
Source: Blood - May 15, 2019 Category: Hematology Authors: Lee, J. K., Kang, S., Wang, X., Rosales, J. L., Gao, X., Byun, H.-G., Jin, Y., Fu, S., Wang, J., Lee, K.-Y. Tags: Free Research Articles, Myeloid Neoplasia, Lymphoid Neoplasia, CME article Source Type: research
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells
Chimeric antigen receptor (CAR) T cells have emerged as a promising class of cell-based immunotherapy in refractory malignancies. Neurotoxicity represents a common and potentially life-threatening adverse effect of CAR T cells, and clinical experience is limited. Here, we describe the clinical presentation and management of 25 adult patients who presented with neurotoxic syndromes after CAR T-cell therapy at the Massachusetts General Hospital. This cohort includes 24 patients treated with CD19-directed CAR T cells for non-Hodgkin lymphoma (n = 23) and acute lymphoblastic leukemia (n = 1), and 1 patient treated with α...
Source: Blood - May 15, 2019 Category: Hematology Authors: Karschnia, P., Jordan, J. T., Forst, D. A., Arrillaga-Romany, I. C., Batchelor, T. T., Baehring, J. M., Clement, N. F., Gonzalez Castro, L. N., Herlopian, A., Maus, M. V., Schwaiblmair, M. H., Soumerai, J. D., Takvorian, R. W., Hochberg, E. P., Barnes, J. Tags: Immunobiology and Immunotherapy, Clinical Trials and Observations Source Type: research
